Original Article

Antagonist protocol versus clomiphene in unexplained infertility: A randomized controlled study

Adel M. Nada [a], Khaled A. ElSetohy [a, *], Moh'd M. Banat [b], Ahmed F. Shaheen [c]

[a] Faculty of Medicine, Department of Gynecology and Obstetrics, Cairo University, Cairo, Egypt
[b] Monash University, Melbourne, Australia
[c] Faculty of Medicine, Department of Andrology, Beni Suef University, Egypt

A R T I C L E   I N F O

A B S T R A C T

Objective: The primary purpose of this randomized controlled trial study was to compare clinical pregnancy rates and ovulation parameters in female patients of unexplained infertility undergoing intrauterine insemination (IUI) using an antagonist protocol versus a conventional clomiphene citrate protocol.
Materials and methods: This was a multicenter parallel randomized controlled, open-label trial. A central randomization center used computer generated tables to allocate treatments. We conducted the study in two centers: Saudi Center and Samir Abbas and Assisted Reproductive Techniques Center of Cairo University, Cairo, Egypt between January 2011 and January 2014. Six hundred and twenty-two couples with unexplained infertility were randomized into two equal groups with 27 excluded after randomization: the antagonist protocol group and the clomiphene group. Antagonist protocol: human menopausal gonadotropins were given to 298 patients from Day 2 to reach a dominant follicle of 18–22 mm, intramuscularly. Then, orgalutrone (0.25 mg) was subcutaneously started from Day 6 or Day 7 until the day of human chorionic gonadotropins (hCG; that was given in the dose of 10,000 IU, intramuscularly) when follicles reached 18–22 mm. Afterward, the IUI of 0.5 mL was done from 34 hours to 36 hours using IUI catheter without guidance of ultrasonography and with an empty urinary bladder. The clomiphene citrate protocol was clomiphene citrate given 100 mg/d to 297 patients from Day 2 to Day 6 and follow up until day of hCG. The clinical pregnancy rate detected with ultrasound confirmed fetal heart pulsations at 6-weeks' gestation (4 weeks after IUI). The number of dominant follicles, level of serum estradiol, and luteinizing hormone at the day of hCG injection and the incidence of twin or triplet pregnancies in both groups were secondary outcome measures.
Results: The clinical pregnancy rate in the antagonist protocol group was significantly ($p < 0.001$) higher than in the clomiphene group. It was 80 patients (27%) in the antagonist protocol group versus 41 patients (14%) in the clomiphene group. The mean number of dominant follicles was significantly ($p < 0.001$) greater in the antagonist protocol group (4.36 ± 1.36 dominant follicles) compared with the clomiphene group (2.71 ± 0.96 dominant follicles). In addition, the rate of twin pregnancies was 15 cases in the antagonist protocol group versus six cases only in the clomiphene group ($p = 0.047$). The luteinizing hormone also was significantly lower in the antagonist group (2.1 ± 1.3) compared with that in the clomiphene group (9.5 ± 3.6).
Conclusion: IUI clinical pregnancy rates were significantly higher by antagonist protocol.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Results of intrauterine insemination (IUI) done in natural menstrual cycles are subtle [1,2]. That is why most clinics use IUI in controlled ovarian hyperstimulation cycles. In addition, there is inadequate evidence to recommend or advise against IUI, either

* Corresponding author. Giza, 3rd Alsaraya Street, Almanyal, Egypt.
E-mail address: kelsetohy@gmail.com (K.A. ElSetohy).

with or without ovarian hyperstimulation, above the conventional timed intercourse or the reverse [3].

However, the need for IUI is still high because the prevalence of unexplained infertility is up to 20% for couples after the initial diagnostic workup. This number may increase if cases of mild male infertility added to it [4].

Superovulation with usual doses of gonadotropins induces pregnancy in 10–15% of couples, as stated by large clinical trials [1,5,6]. The drawbacks of this method were an increase in the incidences of twin pregnancy (15–20%) and triplets (5–10%), thus rendering IUI as an unsafe technique in stimulated cycles [5–11]. It is a simple, noninvasive, and non-expensive method in assisted reproductive techniques but with a low pregnancy rate.

Many studies have proved the value of gonadotropin-releasing hormone antagonist as an effective method to prevent premature luteinization. However, most of these studies failed to find a significant improvement in clinical pregnancy rates in ovarian induction IUI cycles [12].

Hence, the rationale intended for this randomized controlled study was to test the hypothesis that the antagonist protocol can lead to a higher rate of pregnancy in patients with unexplained infertility undergoing IUI, than the standard or the most common protocol using clomiphene citrate without premature rise of luteinizing hormone (LH).

Materials and methods

The study was conducted in the Saudi centers Samir Abbass and Assisted Reproductive Techniques Center of Cairo University, Cairo, Egypt during the period from January 2011 to January 2014.

Ethics

This study followed the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act, and was approved by the Medical Ethical Review Committee of Cairo University and Samir Abbas Ethical Committees.

The purpose of this study was clearly explained in Arabic language to all participants before their enrolment to the study, and an informed consent form was signed by and obtained from all of those enrolled.

We recruited to this study couples with unexplained infertility that were eligible to undergo IUI. Criteria of unexplained infertility was as follows: (1) women with a body mass index 18–30 kg/m^2 with unexplained infertility; with (2) confirmed bilateral patent fallopian tubes (hysterosalpingography or laparoscopy); in addition to (3) normal ovulation evidenced by midluteal serum progesterone > 10 ng/mL and regular menstrual cycles; and finally (4) husband semen analysis with mean sperms count > 15 million sperm/m:, motility > 32%, and morphology > 4% normal form [13].

Female patients with bilateral tubal block, uterine distorted anatomy (submucous fibroids or Asherman syndrome), and hydrosalpinx were not included. In addition, female patients with hyperprolactinemia or thyroid dysfunction were excluded.

All eligible patients were randomized into the two study groups using the matched pairs randomized block design based on age and period of infertility. The two study groups were the antagonist protocol group and the clomiphene citrate protocol group.

Procedures

All enrolled patients were subjected to a full history taking, general and local examination. Hormonal profile and pelvic ultrasound were done for female patients and semen analysis after 4–7 days of abstinence was done for male patients.

Women assigned to the clomiphene group were given clomiphene citrate (Clomid, Sanofi-Aventis, Bourgoin-Jallieu, France) 100 mg from Day 2 to Day 6. Then, the monitoring of ovulation was continued until the dominant follicle (DF) was 18–22 mm. Hence, LH and estradiol were measured, and human chorionic gonadotropin (hCG; Choriomon; IBSA, Lugano, Switzerland) was given at a dose of 10,000 IU, intramuscularly. Afterwards, IUI of 0.5 mL was done from 34 hours to 36 hours, using an IUI catheter without guidance of ultrasonography and with an empty urinary bladder.

However, women assigned to the antagonist protocol group were given human menopausal gonadotropins (Merional; IBSA) from Day 2 to reach a DF of 18–22 mm. The LH was then measured and ganirelix acetate (Orgalutrone; Merck Sharp & Dohme, Quebec, Canada) 0.25 mg subcutaneously was started from Day 6 or Day 7 until the day of hCG that was given in the dose of 10,000 IU intramuscularly when follicles reached 18–22 mm. Afterwards, the IUI of 0.5 mL was done from 34 hours to 36 hours using an IUI catheter without guidance of ultrasonography and with an empty urinary bladder. The aims of these modifications were to avoid premature LH surge and to ensure a high oocyte count available at the time of insemination. Both groups had the same luteal phase support by cyclogest 400 mg vaginal suppository for 2 weeks.

The primary end point was clinical pregnancy rate, as detected by the presence of an intrauterine sac with positive heart pulsations at 6-weeks' gestation done at 4 weeks after IUI in each group. The secondary end points were the number of DFs, levels of LH, and serum estradiol at the day of hCG injection and the incidence of twin or triplet pregnancy in both groups.

Statistical analysis

All statistical tests were done using a significance level of 95%. A value for $p < 0.05$ was considered statistically significant. SPSS software (version 20.0, SSPS Inc., Chicago, IL, USA) was used for the statistical analyses. Data were presented as mean ± standard deviation for continuous variables and as frequency and percent for categorical variables. Comparisons between the two groups were done using Pearson Chi-square test for categorical variable and the unpaired Student t test for continuous variables.

A sample size calculation was done to calculate the number of patients needed in each group, with an alpha level < 0.05 and power > 90%. The sample size used was sufficient to achieve a power more than 90%.

Results

All patients (655) who came to the centers were asked to participate in the study. Twenty-three patients refused to participate, and 10 patients were excluded before randomization for different causes; thus, leaving a population of 622 eligible patients who were randomized in this trial. Twenty-seven patients were excluded after randomization. The dispositions of these patients are shown in Figure 1.

Baseline characteristics

Six hundred and twenty-two couples suffering from infertility were enrolled in this study, after being randomly assigned to two groups, 311 in each. Only 595 patients were included in the analysis. There was no statistically significant difference ($p > 0.05$) between both groups regarding the age, duration, and type of

Figure 1. Consort diagram. hCG = human chorionic gonadotropins; IUI = intrauterine insemination; PP = per protocol; US = ultrasound.

infertility, and the male partner quality of semen (concentration and motility), as shown in Table 1, respectively. Also, there was a no statistically significant difference ($p > 0.05$) between both groups regarding the mean progressive motility percent before processing, as shown in Table 1.

Semen quality before and after preparation

We conducted only one trial of IUI therapy for candidates in both groups. There was no statistically significant difference in semen quality in terms of concentration ($p > 0.05$), progressive motility ($p > 0.05$), and morphology between the two study groups either before or after preparation, as shown in Table 1. Before preparation, the mean semen concentration in the antagonist protocol group was 38.98 ± 9.18 million and in the clomiphene group was 39.92 ± 10.47 million ($p = 0.124$). After preparation, the mean semen concentration was 23.46 ± 8.32 million in the antagonist protocol group and 24.87 ± 7.80 million in the clomiphene group ($p = 0.554$). Additionally, the progressive motility before preparation in the antagonist protocol group 40.51 ± 8.35% and the clomiphene group was 39.55 ± 6.96% ($p = 0.234$). After preparation,

the progressive motility in the antagonist protocol group 89.20 ± 5.28% and the clomiphene group was 90.52 ± 3.65% ($p = 0.117$), as shown in Table 1.

Primary outcome of the study

The number and rate of clinical pregnancy as determined by the presence of fetal heart pulsations at 6-weeks' gestation was 80 patients (27%) in the antagonist protocol group and 41 patients (14%) in the clomiphene group, ($p = 0.000$); as shown in Table 1.

Secondary outcomes of the study

The mean number of DFs was greater in the antagonist protocol group (4.36 ± 1.36 DF) compared with that of the clomiphene group (2.71 ± 0.96 DF). Statistically, this difference is very highly significant with $p < 0.001$. In addition, there was a highly significant difference detected between both groups regarding estrogen level at hCG day, as shown in Table 1. LH also was significantly lower in antagonist group (2.1 ± 1.3) compared with that in the clomiphene group (9.5 ± 3.6; $p < 0.001$).

Table 1
Patient characteristics and study outcomes.

	Antagonist protocol	Clomiphene citrate protocol	*p*
	N = 298	*N* = 297	
Age (y)	30.4 (5.72)	30.06 (5.00)	0.442
Infertility duration (y)	5.66 (2.21)	5.38 (2.72)	0.396
BMI	24.2 (3.1)	24.3 (3.3)	0.243
Infertility type			
Primary	187 (62.75)	190 (63.97)	0.757
Secondary	111 (37.25)	107 (36.03)	
Semen concentration before preparation (in millions)	38.98 (9.18)	39.92 (10.47)	0.124
Progressive motility before preparation	40.51 (8.35)	39.55 (6.96)	0.234
Morphology (% of normal forms)	44 (10.4)	45 (14.3)	0.390
Semen concentration after preparation (in millions)	23.46 (8.32)	24.87 (7.80)	0.554
Progressive motility after preparation	89.20 (5.28)	90.52 (3.65)	0.117
Clinical pregnancy rate	80 (27)	41 (14)	<0.001
Twins	15 (5)	6 (2)	0.047
No. of dominant follicles	4.36 (1.36)	2.71 (0.96)	<0.001
Estradiol level at hCG d	902.62 (305.48)	494.80 (226.12)	<0.001
LH at d of hCG	2.1 (1.3)	9.5 (3.6)	<0.001
Direct cost of 1 cycle in Saudi Rials	1600 ± 200	50 ± 20	<0.001
Mild ovarian hyperstimulation	30 (10)	6 (2)	<0.001
Severe ovarian hyperstimulations	0	0	—

Data are presented as *n* (%) or mean ± standard deviation.
BMI = body mass index; hCG = human chorionic gonadotropin; LH = luteinizing hormone.

Moreover, there was a significant difference detected between both groups in the rate of twin pregnancies, where the number of twin pregnancies in the antagonist protocol group were 15 compared with six cases only in the clomiphene group ($p = 0.047$), as shown in Table 1. Moreover, both groups showed no triplet pregnancies.

Mild ovarian hyperstimulation syndrome (OHSS) occurred in 30 (10%) of the antagonist protocol group versus six (2%) of the clomiphene group ($p < 0.001$). No severe OHSS occurred in both groups.

In addition, the antagonist protocol has a very high direct cost [1600 ± 200 Saudi Rials (SR)] compared with only (50 ± 20 SR) for the clomiphene protocol.

Discussion

The current study showed that there is a significant increase in the rate of clinical pregnancies in the antagonist protocol arm versus the clomiphene citrate arm. Secondary outcomes showed a very highly significant increase both in the level of serum estradiol at the day of hCG and the number of DFs, favoring the arm of antagonist protocol. There is also a marked significant reduction in LH level before hCG in the antagonist group. Moreover, the twin pregnancy rate was higher in the antagonist protocol arm than in the clomiphene citrate arm. This was evident as there were 80 patients (27%) of the antagonist protocol and only 41 patients (14%) of the clomiphene group who proved to be pregnant. In addition, the mean serum LH was significantly lower in the antagonist group (2.1 ± 1.3) compared with the clomiphene group (9.5 ± 3.6). Moreover, the mean serum estradiol on the day of hCG was 902.62 pg/dL in the antagonist protocol group compared with 494.80 pg/dL in the clomiphene group. Moreover, the mean number of DFs was 4.36 in the antagonist protocol group versus 2.71 in the clomiphene citrate group.

To the best of our knowledge of the literature, this is the first study to compare the antagonist protocol with clomiphene citrate.

The results of this study are in favor of the antagonist protocol. Moreover, the rationale behind the hypothesis that the antagonist protocol would increase the rate of clinical pregnancy by increasing the number of follicles and serum estradiol at the day of hCG was

well met in our study. In addition, reduced LH in the antagonist group supports that gonadotropin-releasing hormone antagonist has a strong effect on pituitary suppression and prevention of premature luteinization.

We believe this study was very judgmental as the randomization was well controlled, and baseline characteristics of both groups regarding age, duration and type of infertility, and semen analysis characteristics were all insignificantly variable between both groups.

One disadvantage of the use of the gonadotropin antagonist regimen was the very high direct cost (1600 ± 200 SR) compared with only 50 ± 20 SR in the clomiphene group. Another disadvantage is the high risk of multiple pregnancies, yet, in the social traditions in Arab countries, it is an advantage.

Another disadvantage with the antagonist protocol is the high incidence of OHSS: 30 (10%) versus six (2%) in the clomiphene group. However, all reported cases were mild and treated conservatively.

We followed the usual time of IUI after hCG, as there is no consensus about the best time suggested, although it has been mentioned to be anywhere between 12 hours and 60 hours [14].

Although luteal phase support benefit in cycles using antagonist protocol is a matter of unproven research [15—18], we chose to implement luteal support, as it might increase the pregnancy rate [19,20]. Other studies showed that routine luteal-phase support by vaginal suppositories did not improve pregnancy results in clomiphene citrate induced cycles in IUI trials [21] but an evidence-based review recommended to apply luteal-phase support in stimulated IUI cycles only when proven cost-effective [22].

Finally, because the pregnancy outcome of gonadotropin stimulation is significantly higher, it seems more reasonable to compare the protocols with and without antagonists in future studies.

Conclusions

In conclusion, this study was in favor of the routine use of the antagonist protocol in patients with unexplained infertility undergoing IUI procedure. This area of research still needs more investigations to examine other factors that may play a role in the results of IUI.

Conflicts of interest

Acknowledgments

References

[1] Guzick DS, Carson SA, Coutifaris C, Overstreet JW, Factor-Litvak P, Steinkampf MP, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproduction Medicine Network. N Engl J Med 1999;340:177–83.

[2] Cohlen BJ, Vanderkerckhove P, TeVelde ER, Habbema JD. Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men. Cochrane Database Syst Rev 2000;2. CD000360.

[3] Bensdorp AJ, Cohlen BJ, Heineman MJ, Vandekerckhove P. Intra-uterine insemination for male subfertility. Cochrane Database Syst Rev 2007;4. CD000360.

[4] Crosignani PG, Rubin BL. Optimal use of infertility diagnostic tests and treatments. The ESHRE Capri Workshop Group. Hum Reprod 2000;15:723–32.

[5] Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med 2000;343:2–7.

[6] Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Risk factors for high-order multiple pregnancy and multiple birth after controlled ovarian hyperstimulation: results of 4,062 intrauterine insemination cycles. Fertil Steril 2005;83:671–83.

[7] Tur R, Barri PN, Coroleu B, Buxaderas R, Martinez F, Balasch J. Risk factors for high-order multiple implantation after ovarian stimulation with gonadotrophins: evidence from a large series of 1878 consecutive pregnancies in a single centre. Hum Reprod 2001;16:2124–9.

[8] ESHRE Capri Workshop Group. Multiple gestation pregnancy. Hum Reprod 2000;15:1856–64.

[9] Fauser BC, Devroey P, Macklon NS. Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet 2005;365:1807–16.

[10] Cohlen BJ. Should we continue performing intrauterine inseminations in the year 2004? Gynecol Obstet Invest 2005;59:3–13.

[11] Kurinczuk JJ. Safety issues in assisted reproduction technology. From theory to reality—just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? Hum Reprod 2003;18:925–31.

[12] Steward RG, Gill I, Williams DB, Witz CA, Griffith J, Haddad GF. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction-intrauterine insemination cycles: a randomized-controlled clinical trial. Fertil Steril 2011;95:434–6.

[13] Cooper TG, Noonan E, von Eckardstein S, Auger J, Baker HW, Behre HM, et al. World Health Organization reference values for human semen characteristics. Hum Reprod Update 2010;16:231–45.

[14] Ragni G, Maggioni P, Guermandi E, Testa A, Baroni E, Colombo M, et al. Efficacy of double intrauterine insemination in controlled ovarian hyperstimulation cycles. Fertil Steril 1999;72:619–22.

[15] Albano C, Smitz J, Tournaye H, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Luteal phase and clinical outcome after human menopausalgonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles. Hum Reprod 1999;14:1426–30.

[16] De Jong D, Macklon NS, Fauser BC. A pilot study involving mini-mal ovarian stimulation for in vitro fertilization: extending the "follicle- stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 2000;73:1051–4.

[17] Ragni G, Vegetti W, Baroni E, Colombo M, Arnoldi M, Lombroso G, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod 2001;16:2258–62.

[18] Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC, Devroey P. Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2003;80:464–6.

[19] Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum Reprod 2002;17:2287–99.

[20] Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333–40.

[21] Kyrou D, Fatemi HM, Tournaye H, Devroey P. Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit? Hum Reprod 2010;25:2501–6.

[22] Cohlen BJ. Should luteal phase support be introduced in ovarian stimulation/IUI programs? An evidence-based review. Reprod Biomed Online 2009;19(Suppl. 4):4239.